Pulmonary hypertension in women

References

• Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54(1 Suppl.), S43–S54 (2009).
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med.115(5), 343–349 (1991).
   PubMed Web of Science ®Google Scholar
• Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet.26(1), 81–84 (2000).
   PubMed Web of Science ®Google Scholar
• Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA 3rd, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.152(1), 93–97 (1995).
   PubMed Web of Science ®Google Scholar
• Nichols WC, Koller DL, Slovis B et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nat. Genet.15(3), 277–280 (1997).
   PubMed Web of Science ®Google Scholar
• Hamid R, Cogan JD, Hedges LK et al. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum. Mutat.30(4), 649–654 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts KE, McElroy JJ, Wong WP et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J.24(3), 371–374 (2004).
   PubMed Web of Science ®Google Scholar
• Elliott CG, Glissmeyer EW, Havlena GT et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation113(21), 2509–2515 (2006).
   PubMed Web of Science ®Google Scholar
• Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J. Med. Genet.37(10), 741–745 (2000).
   PubMed Web of Science ®Google Scholar
• Hansmann G, de Jesus Perez VA, Alastalo TP et al. An antiproliferative BMP-2/PPARg/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest.118(5), 1846–1857 (2008).
   PubMed Web of Science ®Google Scholar
• Gamell C, Osses N, Bartrons R et al. BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity. J. Cell Sci.121(Pt 23), 3960–3970 (2008).
   PubMed Web of Science ®Google Scholar
• Wojciak-Stothard B, Tsang LY, Haworth SG. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol.288(4), L749–L760 (2005).
   PubMed Web of Science ®Google Scholar
• Wojciak-Stothard B, Tsang LY, Paleolog E, Hall SM, Haworth SG. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol.290(6), L1173–L1182 (2006).
   Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med.327(2), 70–75 (1992).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med.351(14), 1425–1436 (2004).
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D, Yanagisawa M, Forbes RD. Endothelin-1 immunoreactivity and mRNA in the transplanted human heart. Transplantation59(9), 1308–1313 (1995).
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.328(24), 1732–1739 (1993).
   PubMed Web of Science ®Google Scholar
• Champion HC, Bivalacqua TJ, D’Souza FM et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ. Res.84(12), 1422–1432 (1999).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med.173(9), 1023–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest137(2), 376–387 (2010).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(1 Suppl.), S55–S66 (2009).
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med.107(2), 216–223 (1987).
   PubMed Web of Science ®Google Scholar
• Austin ED, Cogan JD, West JD et al. Alterations in estrogen metabolism: implications for higher penetrance of FPAH in females. Eur. Respir. J.34(5), 1093–1099 (2009).
   PubMed Web of Science ®Google Scholar
• Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet.68(1), 92–102 (2001).
   PubMed Web of Science ®Google Scholar
• Kawut SM, Krowka MJ, Trotter JF et al. Clinical risk factors for portopulmonary hypertension. Hepatology48(1), 196–203 (2008).
   PubMed Web of Science ®Google Scholar
• Roberts KE, Fallon MB, Krowka MJ et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am. J. Respir. Crit. Care Med.179(9), 835–842 (2009).
   PubMed Web of Science ®Google Scholar
• Chung L, Liu J, Parsons L et al. Characterization of connective tissue disease associated pulmonary arterial hypertension from the REVEAL registry: identifying systemic sclerosis as a unique phenotype. Chest DOI: 10.1378/chest.10-0260 (2010) (Epub ahead of print).
   Google Scholar
• Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum.54(9), 3043–3050 (2006).
   PubMed Web of Science ®Google Scholar
• Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum.37(4), 223–235 (2008).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol.53(17), 1573–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111(23), 3105–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med.149(8), 521–530 (2008).
   PubMed Web of Science ®Google Scholar
• Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest112(3), 714–721 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J.28(5), 999–1004 (2006).
   PubMed Web of Science ®Google Scholar
• Collins N, Bastian B, Quiqueree L, Jones C, Morgan R, Reeves G. Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). Eur. J. Echocardiogr.7(6), 439–446 (2006).
   PubMed Web of Science ®Google Scholar
• Sweeney L, Voelkel NF. Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur. J. Med. Res.14(10), 433–442 (2009).
   PubMed Web of Science ®Google Scholar
• Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G. 2-methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul. Pharmacol.45(6), 358–367 (2006).
   PubMed Web of Science ®Google Scholar
• Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul. Pharmacol.51(2–3), 190–197 (2009).
   PubMed Web of Science ®Google Scholar
• Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul. Pharmacol.51(2–3), 190–197 (2009).
   PubMed Web of Science ®Google Scholar
• Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G. 2-ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul. Pharmacol.48(4–6), 174–183 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis19(1), 1–27 (1998).
   PubMed Web of Science ®Google Scholar
• Meldrum DR. G-protein-coupled receptor 30 mediates estrogen’s nongenomic effects after hemorrhagic shock and trauma. Am. J. Pathol.170(4), 1148–1151 (2007).
   PubMed Web of Science ®Google Scholar
• Lahm T, Patel KM, Crisostomo PR et al. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am. J. Physiol. Endocrinol. Metab.293(3), E865–E871 (2007).
   Google Scholar
• Lahm T, Crisostomo PR, Markel TA et al. Selective estrogen receptor-α and estrogen receptor-β agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol.295(5), R1486–R1493 (2008).
   Google Scholar
• Moore LG, McMurtry IF, Reeves JT. Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats. Proc. Soc. Exp. Biol. Med.158(4), 658–662 (1978).
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am. J. Physiol.240(1), H62–H72 (1981).
   PubMed Web of Science ®Google Scholar
• McMurtry IF, Frith CH, Will DH. Cardiopulmonary responses of male and female swine to simulated high altitude. J. Appl. Physiol.35(4), 459–462 (1973).
   PubMed Web of Science ®Google Scholar
• Resta TC, Kanagy NL, Walker BR. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am. J. Physiol. Lung Cell. Mol. Physiol.280(1), L88–L97 (2001).
   Google Scholar
• Said SI, Hamidi SA, Dickman KG et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation115(10), 1260–1268 (2007).
   PubMed Web of Science ®Google Scholar
• Hansmann G, Wagner RA, Schellong S et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation. Circulation115(10), 1275–1284 (2007).
   PubMed Web of Science ®Google Scholar
• West J, Harral J, Lane K et al. Mice expressing BMPR2r899x transgene in smooth muscle develop pulmonary vascular lesions. Am. J. Physiol. Lung Cell. Mol. Physiol.295(5), L744–L755 (2008).
   PubMed Web of Science ®Google Scholar
• West J, Fagan K, Steudel W et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ. Res.94(8), 1109–1114 (2004).
   PubMed Web of Science ®Google Scholar
• English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm. Metab. Res.33(11), 645–652 (2001).
   PubMed Web of Science ®Google Scholar
• Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS. Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J. Cardiovasc. Pharmacol.39(6), 814–823 (2002).
   PubMed Web of Science ®Google Scholar
• Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS, Jones RD. Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc. Health Risk Manag.4(6), 1459–1466 (2008).
   PubMedGoogle Scholar
• Farrukh IS, Peng W, Orlinska U, Hoidal JR. Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener. Am. J. Physiol.274(2 Pt 1), L186–L195 (1998).
   Google Scholar
• Homma N, Nagaoka T, Karoor V et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am. J. Physiol. Lung Cell. Mol. Physiol.295(1), L71–L78 (2008).
   Google Scholar
• Oka M, Karoor V, Homma N et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc. Res.74(3), 377–387 (2007).
   PubMed Web of Science ®Google Scholar
• West J, Cogan J, Geraci M et al. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med. Genomics1, 45 (2008).
   PubMedGoogle Scholar
• Diergaarde B, Potter JD, Jupe ER et al. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol. Biomarkers Prev.17(7), 1751–1759 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol. Appl. Pharmacol.199(3), 210–219 (2004).
   PubMed Web of Science ®Google Scholar
• Roos PH, Bolt HM. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin. Drug Metab. Toxicol.1(2), 187–202 (2005).
   PubMedGoogle Scholar
• Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett.221(2), 185–190 (2005).
   PubMed Web of Science ®Google Scholar
• Spivack SD, Hurteau GJ, Reilly AA, Aldous KM, Ding X, Kaminsky LS. CYP1B1 expression in human lung. Drug Metab. Dispos.29(6), 916–922 (2001).
   PubMed Web of Science ®Google Scholar
• Wenzlaff AS, Cote ML, Bock CH et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis26(12), 2207–2212 (2005).
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med.354(3), 270–282 (2006).
   PubMed Web of Science ®Google Scholar
• Muti P, Bradlow HL, Micheli A et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology11(6), 635–640 (2000).
   PubMed Web of Science ®Google Scholar
• Rajkumar R, Konishi K, Richards TJ et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol.298(4), H1235–H1248 (2010).
   PubMed Web of Science ®Google Scholar
• Wagner JD, Kaplan JR, Burkman RT. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet. Gynecol. Clin. North Am.29(3), 475–493 (2002).
   PubMed Web of Science ®Google Scholar
• Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand. J. Rheumatol.35(6), 468–471 (2006).
   PubMed Web of Science ®Google Scholar
• Morse JH, Horn EM, Barst RJ. Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest116(3), 847 (1999).
   PubMedGoogle Scholar
• Ventetuolo CE, Ouyang P, Bluemke DA et al. Sex hormones and the right ventricle: the MESA-right ventricle study. Am. J. Respir. Crit. Care Med.179 (2009) (Abstract A4150).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Yaici A et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J.36(3), 549–555 (2010).
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension. Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation122(2), 164–172 (2010).
   PubMed Web of Science ®Google Scholar
• Kawut SM, Al-Naamani N, Agerstrand C et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest135(3), 752–759 (2009).
   PubMed Web of Science ®Google Scholar
• Tandri H, Daya SK, Nasir K et al. Normal reference values for the adult right ventricle by magnetic resonance imaging. Am. J. Cardiol.98(12), 1660–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation119(22), 2894–2903 (2009).
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353(20), 2148–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346(12), 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol.46(3), 529–535 (2005).
   PubMed Web of Science ®Google Scholar
• Higenbottam T. Intravenous epoprostenol for primary pulmonary hypertension. N. Engl. J. Med.334(22), 1477; author reply 1477–1478 (1996).
   PubMedGoogle Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation106(12), 1477–1482 (2002).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med.334(5), 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med.347(5), 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol.48(7), 1433–1437 (2006).
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J.34(6), 1219–1263 (2009).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(1 Suppl.), S78–S84 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J. Am. Coll. Cardiol.31(7), 1650–1657 (1998).
   PubMed Web of Science ®Google Scholar
• Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur. Heart J.30(3), 256–265 (2009).
   PubMed Web of Science ®Google Scholar
• Hemnes AR, Robbins IM. Hysteroscopic sterilization in women with pulmonary vascular disease. Mayo Clin. Proc.83(10), 1188–1189; author reply 1189 (2008).
   PubMedGoogle Scholar
• Hansmann G, Rabinovitch M. The protective role of adiponectin in pulmonary vascular disease. Am. J. Physiol. Lung Cell. Mol. Physiol.298(1), L1–L2 (2010).
   Google Scholar
• Rabinovitch M. PPARg and the pathobiology of pulmonary arterial hypertension. Adv. Exp. Med. Biol.661, 447–458 (2010).
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Hansmann G, Snook S et al. Insulin resistance in pulmonary arterial hypertension. Eur. Respir. J.33(2), 318–324 (2009).
   PubMed Web of Science ®Google Scholar
• Robbins IM, Newman JH, Johnson RF et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest136(1), 31–36 (2009).
   PubMed Web of Science ®Google Scholar